ARTICLE | Company News
Scriptgen other research news
October 30, 1995 8:00 AM UTC
The Medford, Mass., company received five Phase I SBIR grants totaling $500,000 from the National Institute of Allergy and Infectious Diseases to develop orally active compounds.
The first two grants will be used to develop screens to find an oral inhibitor for tuberculosis and for systemic candidiasis. ...